Alzinova AB (publ) (STO:ALZ)

Revenue by Product

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2014
Period Ending	Dec 31, 2023	Dec 31, 2014
Oligomer-specific Vaccine and Monoclonal Antibody	270.00K
Oligomer-specific Vaccine and Monoclonal Antibody Growth	1111.09%

Revenue by Geography

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2014
Period Ending	Dec 31, 2023	Dec 31, 2014
Sweden	270.00K
Sweden Growth	1111.09%